Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|
Gross Profit | $1,652.4M | $1,877.4M | $1,564.7M | $1,658.9M | $794.9M | $2,033.9M | $2,266.5M | $2,231.5M | $1,793.9M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Royalty Pharma plc's last 12-month Gross Profit is $1,598.2M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Royalty Pharma plc's Gross Profit growth was (4.9%). The average annual Gross Profit growth rates for Royalty Pharma plc have been (7.9%) over the past three years, 7.5% over the past five years.